• Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
5,284
On Slideshare
0
From Embeds
0
Number of Embeds
11

Actions

Shares
Downloads
3
Comments
0
Likes
3

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849

Transcript

  • 1. 3 Humongous Health-Care Stocks This Week
  • 2. A lot of health-care stocks took a beating this week. Not all of them, though. Here are the three most humongous health-care stocks over the week ending April 11, 2014.
  • 3. Shares of the biopharmaceutical firm soared 22% this week. Agios Pharmaceuticals (Nasdaq: AGIO) Source: Yahoo! Finance
  • 4. • Positive phase 1 preliminary data was announced for cancer drug AG-221. • Agios reported AG-221 was well tolerated but with two possible drug- related severe adverse events. • Clinical results were promising, with multiple complete remissions in patients with blood cancer. • Celgene (Nasdaq: CELG) stands as another winner, as AG-221 is part of a collaboration established between the big biotech and Agios in 2010. Why Agios shares took off
  • 5. Shares of the biotech climbed 18% higher for the week. Questcor Pharmaceuticals (Nasdaq: QCOR) Source: Yahoo! Finance
  • 6. • Specialty pharmaceutical company Mallinckrodt (NYSE: MNK) is acquiring Questcor. • Shareholders will receive $30 in cash and 0.897 Mallinckrodt shares for each Questcor share they own. • The deal represents a 27% premium over Questcor’s closing price before the announcement. Why Questcor shot up
  • 7. Shares of the clinical-stage biotech jumped nearly 18% this week. Bio-Path Holdings (Nasdaq: BPTH) Source: Yahoo! Finance
  • 8. • No big announcements this week from Bio-Path. • The biotech looks to be rebounding from a sell-off that started in late February. • Bio-Path’s Liposomal Grb-2 is in phase 1 clinical studies targeting several forms of leukemia and myelodysplastic syndrome. Why Bio-Path boomed
  • 9. • Questcor won’t shoot up significantly, since the price of the acquisition by Mallinckrodt is set. • Bio-Path Holdings could continue its rebound, but major new developments are still in the future. • Agios’ early-stage results for AG-221 show considerable promise . • The partnership with Celgene gives Agios a leg up in continued development of the blood cancer drug. • A possibility also exists that Celgene could use some of its $5.6 billion in cash and short-term investments to scoop up Agios down the road. Best pick to stay humongous?
  • 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!